VIAject: Phase III data

Biodel Inc. (NASDAQ:BIOD), Danbury, Conn. Product: VIAject Business: Endocrine Molecular target: Insulin receptor Description: Injectable recombinant human insulin Indication: Treat Type I diabetes E...